OS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation
I'm PortAI, I can summarize articles.
OS Therapies Inc. has unveiled its cancer immunotherapy pipeline, highlighting the OST-HER2 program targeting osteosarcoma, with potential applications in breast cancer and other tumors. The company aims for accelerated approval by 2026 and projects a Priority Review Voucher sale of $160 million. The pipeline includes candidates for various cancers, with a market cap of $60 million and cash holdings of $4 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments